Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

NASDAQ:PVLA - Nasdaq - US6979471090 - Common Stock - Currency: USD

40.9  +1.85 (+4.74%)

After market: 40.9 0 (0%)

Fundamental Rating

3

Taking everything into account, PVLA scores 3 out of 10 in our fundamental rating. PVLA was compared to 551 industry peers in the Biotechnology industry. While PVLA has a great health rating, there are worries on its profitability. PVLA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PVLA had negative earnings in the past year.
PVLA had a negative operating cash flow in the past year.
In the past 5 years PVLA always reported negative net income.
In the past 5 years PVLA always reported negative operating cash flow.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -26.10%, PVLA is doing good in the industry, outperforming 71.51% of the companies in the same industry.
PVLA has a better Return On Equity (-37.30%) than 72.41% of its industry peers.
Industry RankSector Rank
ROA -26.1%
ROE -37.3%
ROIC N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
PVLA has more shares outstanding than it did 1 year ago.
PVLA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PVLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 9.44 indicates that PVLA is not in any danger for bankruptcy at the moment.
PVLA has a better Altman-Z score (9.44) than 85.84% of its industry peers.
There is no outstanding debt for PVLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.44
ROIC/WACCN/A
WACC11.09%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PVLA has a Current Ratio of 8.84. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PVLA (8.84) is better than 74.41% of its industry peers.
PVLA has a Quick Ratio of 8.84. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.84, PVLA is doing good in the industry, outperforming 74.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.84
Quick Ratio 8.84
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.90%, which is quite impressive.
PVLA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)45.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.27%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

PVLA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.94% yearly.
The Revenue is expected to grow by 620.76% on average over the next years. This is a very strong growth
EPS Next Y1.69%
EPS Next 2Y-1.39%
EPS Next 3Y-11.94%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y620.76%
Revenue Next 5YN/A

3.3 Evolution

PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 10M 20M 30M 40M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PVLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PVLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

A cheap valuation may be justified as PVLA's earnings are expected to decrease with -11.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.39%
EPS Next 3Y-11.94%

More info and screens

0

5. Dividend

5.1 Amount

PVLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (8/8/2025, 8:01:54 PM)

After market: 40.9 0 (0%)

40.9

+1.85 (+4.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners37.73%
Inst Owner Change1.57%
Ins Owners17.8%
Ins Owner Change0.59%
Market Cap452.35M
Analysts82.67
Price Target50.21 (22.76%)
Short Float %8.51%
Short Ratio4.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-136.67%
Min EPS beat(2)-313.44%
Max EPS beat(2)40.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.23%
EPS NQ rev (1m)-1.15%
EPS NQ rev (3m)46.03%
EPS NY rev (1m)-10.64%
EPS NY rev (3m)46.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.14
P/tB 8.14
EV/EBITDA N/A
EPS(TTM)-6.89
EYN/A
EPS(NY)-3.15
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.1%
ROE -37.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.84
Quick Ratio 8.84
Altman-Z 9.44
F-Score4
WACC11.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.27%
EPS Next Y1.69%
EPS Next 2Y-1.39%
EPS Next 3Y-11.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y620.76%
Revenue Next 5YN/A
EBIT growth 1Y-195.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-92.41%
EBIT Next 3Y-70.53%
EBIT Next 5YN/A
FCF growth 1Y78.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.02%
OCF growth 3YN/A
OCF growth 5YN/A